Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...

(RTTNews) - Below are the earnings highlights for AbbVie (ABBV): Earnings: -$22 million in Q4 vs. $822 million in the same period last year. EPS: -$0.02 in Q4 vs. $0.46 in the same period last year.

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news begins with adjusted earnings per share of $2.16 easily beating Wall Street ...

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...

Shares of AbbVie Inc. (NYSE:ABBV) surged after the company reported strong Q4 2024 results and provided in-line revenue guidance and better-than-expected EPS guidance for 2025. I am very pleased ...

AbbVie expects full-year earnings in the range of $12.12 to $12.32 per share. AbbVie shares have fallen 1% since the beginning of the year, while the S&P’s 500 index has increased 27%. The stock ...

We provide aggregated data on dividend stocks. AbbVie has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank ...

“Both Skyrizi and Rinvoq together are already capturing roughly one-third of the UC in-play market, which supports robust momentum going forward for both AbbVie brands.” “We are very pleased ...

Well before the market open, news broke of those two AbbVie price target increases. They came at the kickoff of the week, when the company was scheduled to post its fourth-quarter earnings (on ...

CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total net revenues for the year, up 4.6% operationally, despite $5 billion in ...